Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Taxes Change in Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Shares Issued Shares Repurchased

Growth Metrics

Ratios

Avai Bio (AVAI) Change in Receivables (2020 - 2023)

Avai Bio's Change in Receivables history spans 3 years, with the latest figure at $64444.0 for Q1 2023.

On a quarterly basis, Change in Receivables changed N/A to $64444.0 in Q1 2023 year-over-year; TTM through Mar 2023 was $3765.0, a N/A change, with the full-year FY2023 number at $3765.0, down 93.71% from a year prior.
Change in Receivables hit $64444.0 in Q1 2023 for Avai Bio, up from -$57800.0 in the prior quarter.
Over the last five years, Change in Receivables for AVAI hit a ceiling of $64444.0 in Q1 2023 and a floor of -$64066.0 in Q2 2020.
Historically, Change in Receivables has averaged -$10692.2 across 3 years, with a median of -$8397.0 in 2020.